Marc Quartulli Joins TISSIUM as Vice President of Clinical Affairs

TISSIUM has welcomed a new member to its executive team, hiring Marc Quartulli as vice president of Clinical Affairs.

Quartulli’s recruitment reflects the company’s continued focus on advancing its clinical strategy, generating robust clinical evidence to support regulatory approvals and adoption, and strengthening its readiness for commercialization in key markets. The company continues to build its capabilities in the United States and Europe to create the future of tissue reconstruction.

“Marc brings a strong track record in leading global clinical programs and translating innovative technologies into meaningful clinical outcomes,” TISSIUM Deputy CEO/Chief Innovation Officer Maria Pereira stated. “His expertise will be essential as we continue to expand our clinical footprint in our three indications (atraumatic peripheral nerve repair, atraumatic hernia repair, cardiovascular sealing) and accelerate the development of our platform to benefit patients worldwide.”

Quartulli has extensive experience in clinical development and medical affairs across the medical device industry. Most recently, he was vice president, Clinical Affairs at AlvaMed Inc. Before that, he held senior leadership roles at Conformis, including vice president of Clinical Affairs, Professional Affairs & Market Access, leading global clinical strategies and supporting market access initiatives for innovative orthopedic solutions.

“I am excited to join TISSIUM at such a pivotal time in its development,” Quartulli said. “The potential of its technology to address significant unmet needs in tissue reconstruction is highly compelling. I look forward to working closely with surgeons and clinical partners to advance robust clinical programs and help bring these innovations to patients.”

A privately-owned medtech company based in Paris and Boston, TISSIUM develops and commercializes products derived from its unique biopolymer platform. The products address multiple unmet clinical needs, including atraumatic tissue repair and reconstruction. TISSIUM is developing a product portfolio that leverages its proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are the foundation of the company’s technology platform. Currently, the company has a pipeline of seven products across three verticals, including sutureless nerve repair, hernia repair, and cardiovascular sealants. Each product is designed to enhance the tissue reconstruction process in a unique way. In addition, the company develops complementary delivery and activation devices for enhanced performance and usability of its products. TISSIUM’s technology is based on research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who cofounded the company in 2013.